

2023 Pharmacogenomics: Propelling Practice and Proof in Populations Symposium

Rooms E115 and E113 475 N. 5th Street, Phoenix, AZ 85004.

Friday, January 13, 2023	
9-9:25 a.m.	Registration /
9:25-9:30 a.m.	Welcome/Opening: Will Heise
9:30-10:30 a.m.	David Oslin, MD, PI for VA PrimeCare Study – PGX for Depression Next Steps
10:30-11:30 a.m.	Laura Ramsey MD, University of Cincinnati – PGx and Peds
11:30-12:30 p.m.	Lunch
12:30-1:30 p.m.	Tara Sklar, JD, University of Arizona – Arizona Biomarker laws and state requirements for testing
1:30-2:15 p.m.	Francisco Moreno MD, PI All of US Arizona – All of US and PGx
2:15-2:35 p.m.	Ayrn O'Connor, MD, Banner Health – Topic TBD
2:35-2:55 p.m.	Mark Zubriski, MD, VA Phoenix – PHASER project update
3:00-3:20 p.m.	Tyler Gallo, Pharm D – Evaluation of actionable PGx recommendations in VA patients
3:25-4:10 p.m.	CW Heise, MD – Initial reaction to PGX Clinical Decision support at Banner
4:15-5:00 p.m.	Open discussion with attendees and faculty (on outside patio)

College of Medicine – Phoenix Pharmacogenomics: Propelling Practice and Proof in Populations Symposium

Outcome Objectives:

- 1) Identify patients that would benefit from PGx.
- 2) Identify medications/conditions that are most likely to be impacted by genetic variations.
- 3) Identify situations where PGx testing and evaluation would benefit patients.